<DOC>
	<DOCNO>NCT00836485</DOCNO>
	<brief_summary>This phase 2 study consist 4 visit 5 week period . Drug evaluate use conjunctival allergen challenge model allergic conjunctivitis .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Ketotifen 4.0 % Patch Compared Placebo Patch , Olopatadine 0.2 % Ophthalmic Solution , Artificial Tears Conjunctival Allergen Challenge ( CAC ) Model Acute Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<mesh_term>Ketotifen</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>18 year age either sex race positive history ocular allergy positive skin test reaction cat hair , cat dander , dog dander , grass , ragweed , tree , dust mite , and/or cockroach within past 24 month able willing avoid disallow medication washout period study active ocular infection skin condition ocular surgery within past 3 month pregnancy nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>